Accelerate development by outsourcing MRNA-LNP formulations to a CDMO

Поділитися
Вставка
  • Опубліковано 28 бер 2023
  • RNA-lipid nanoparticle (LNP) vaccines have highlighted the impact of genetic medicines deployed at scale. RNA-LNP applications include gene editing, oncology, and rare diseases.
    A common need for these RNA-LNP therapies is a scalable manufacturing process, as development of RNA-LNPs can be time consuming, cost prohibitive and require deep expertise. In a field that is extremely dynamic and accelerating fast, key solutions such as outsourcing can provide direct and valuable access to infrastructure, experience, and meaningful data.
    Learn more about BioPharma Services - www.precisionnanosystems.com/...
    Follow us on LinkedIn: bit.ly/3F9uEiL
    Follow us on Twitter: bit.ly/3yBttpW
  • Наука та технологія

КОМЕНТАРІ •